Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

The Duffy binding protein as a key target for a Plasmodium vivax vaccine: lessons from the Brazilian Amazon.

de Sousa TN, Kano FS, de Brito CF, Carvalho LH.

Mem Inst Oswaldo Cruz. 2014 Aug;109(5):608-17. Review.

2.

Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.

Ntumngia FB, Schloegel J, McHenry AM, Barnes SJ, George MT, Kennedy S, Adams JH.

Vaccine. 2013 Sep 13;31(40):4382-8. doi: 10.1016/j.vaccine.2013.07.002. Epub 2013 Jul 31.

3.

Antibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmission.

Zakeri S, Babaeekhou L, Mehrizi AA, Abbasi M, Djadid ND.

Am J Trop Med Hyg. 2011 Jun;84(6):944-50. doi: 10.4269/ajtmh.2011.11-0001.

4.

Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians.

Nicolete VC, Frischmann S, Barbosa S, King CL, Ferreira MU.

J Infect Dis. 2016 Nov 15;214(10):1539-1546. Epub 2016 Aug 30.

5.

Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection.

King CL, Michon P, Shakri AR, Marcotty A, Stanisic D, Zimmerman PA, Cole-Tobian JL, Mueller I, Chitnis CE.

Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8363-8. doi: 10.1073/pnas.0800371105. Epub 2008 Jun 3.

6.

Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein.

Grimberg BT, Udomsangpetch R, Xainli J, McHenry A, Panichakul T, Sattabongkot J, Cui L, Bockarie M, Chitnis C, Adams J, Zimmerman PA, King CL.

PLoS Med. 2007 Dec;4(12):e337.

7.

Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys.

Arévalo-Herrera M, Castellanos A, Yazdani SS, Shakri AR, Chitnis CE, Dominik R, Herrera S.

Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):25-31.

PMID:
16291763
8.

Plasmodium vivax Duffy binding protein: baseline antibody responses and parasite polymorphisms in a well-consolidated settlement of the Amazon Region.

Kano FS, Sanchez BA, Sousa TN, Tang ML, Saliba J, Oliveira FM, Nogueira PA, Gonçalves AQ, Fontes CJ, Soares IS, Brito CF, Rocha RS, Carvalho LH.

Trop Med Int Health. 2012 Aug;17(8):989-1000. doi: 10.1111/j.1365-3156.2012.03016.x. Epub 2012 May 30.

9.

The Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic Variants.

Kano FS, Souza-Silva FA, Torres LM, Lima BA, Sousa TN, Alves JR, Rocha RS, Fontes CJ, Sanchez BA, Adams JH, Brito CF, Pires DE, Ascher DB, Sell AM, Carvalho LH.

PLoS Negl Trop Dis. 2016 Dec 13;10(12):e0005177. doi: 10.1371/journal.pntd.0005177. eCollection 2016 Dec.

10.

Targeting the Plasmodium vivax Duffy-binding protein.

Chitnis CE, Sharma A.

Trends Parasitol. 2008 Jan;24(1):29-34. Epub 2007 Nov 26. Review.

PMID:
18023618
11.

Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.

Devi YS, Mukherjee P, Yazdani SS, Shakri AR, Mazumdar S, Pandey S, Chitnis CE, Chauhan VS.

Vaccine. 2007 Jul 9;25(28):5166-74. Epub 2007 May 21.

PMID:
17544179
12.

Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC).

Maestre A, Muskus C, Duque V, Agudelo O, Liu P, Takagi A, Ntumngia FB, Adams JH, Sim KL, Hoffman SL, Corradin G, Velez ID, Wang R.

PLoS One. 2010 Jul 15;5(7):e11437. doi: 10.1371/journal.pone.0011437.

13.

Non-allele specific antibody responses to genetically distinct variant forms of Plasmodium vivax Duffy binding protein (PvDBP-II) in Iranians exposed to seasonal malaria transmission.

Valizadeh V, Zakeri S, Mehrizi AA, Djadid ND.

Acta Trop. 2014 Aug;136:89-100. doi: 10.1016/j.actatropica.2014.03.019. Epub 2014 Apr 2.

PMID:
24704284
14.

Anti-Plasmodium vivax duffy binding protein antibodies measure exposure to malaria in the Brazilian Amazon.

Cerávolo IP, Bruña-Romero O, Braga EM, Fontes CJ, Brito CF, Souza JM, Krettli AU, Adams JH, Carvalho LH.

Am J Trop Med Hyg. 2005 Jun;72(6):675-81.

PMID:
15964949
15.

Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.

Ntumngia FB, King CL, Adams JH.

Int J Parasitol. 2012 Nov;42(12):1055-62. doi: 10.1016/j.ijpara.2012.09.006. Epub 2012 Oct 12. Review.

16.

Duffy antigen receptor for chemokine (DARC) polymorphisms and its involvement in acquisition of inhibitory anti-duffy binding protein II (DBPII) immunity.

Souza-Silva FA, Torres LM, Santos-Alves JR, Tang ML, Sanchez BA, Sousa TN, Fontes CJ, Nogueira PA, Rocha RS, Brito CF, Adams JH, Kano FS, Carvalho LH.

PLoS One. 2014 Apr 7;9(4):e93782. doi: 10.1371/journal.pone.0093782. eCollection 2014.

17.

Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development.

Sampath S, Carrico C, Janes J, Gurumoorthy S, Gibson C, Melcher M, Chitnis CE, Wang R, Schief WR, Smith JD.

PLoS Pathog. 2013;9(6):e1003420. doi: 10.1371/journal.ppat.1003420. Epub 2013 Jun 13.

18.

Strain-Transcending Inhibitory Antibodies against Homologous and Heterologous Strains of Duffy Binding Protein region II.

Wongkidakarn S, McHenry AM, Sattabongkot J, Adams JH, Chootong P.

PLoS One. 2016 May 4;11(5):e0154577. doi: 10.1371/journal.pone.0154577. eCollection 2016.

19.

Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein.

Ntumngia FB, Adams JH.

Clin Vaccine Immunol. 2012 Jan;19(1):30-6. doi: 10.1128/CVI.05466-11. Epub 2011 Nov 23.

Supplemental Content

Support Center